Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females 17 years of age or older~* Stable cancer-related pain.~* Are receiving a stable, fixed-schedule oral opioid regimen equivalent to 60 to 1000 mg of oral morphine per day or transdermal fentanyl therapy equivalent to 50 to 300 µg/h, and are on a stable dose of opioid medication for relief of breakthrough pain for at least 14 days prior to screening.~* Experiencing 1-4 episodes of breakthrough pain per day.~* Meet the criteria defined in the Eastern Cooperative Oncology Group (ECOG) Performance Status for Grade 0, 1, or 2.~Exclusion Criteria:~* Are pregnant or lactating.~* Have uncontrolled or rapidly escalating pain.~* Have moderate to severe ulcerative mucositis.~* Have a cardiopulmonary disease that would increase the risk of administering potent opioids.~* Have neurologic or psychologic disease that would compromise data collection~* Have any clinically significant condition that would, in the investigator's opinion, preclude study participation.~* Are currently taking monoamine oxidase inhibitors (MAOIs), or have taken MAOIs within 14 days prior to enrolling in the study.~* Have received strontium 89 therapy within 60 days prior to entering the study.~* Have received anti-neoplastic therapy within 2 weeks of study entry that, in the investigator's opinion, will influence assessment of breakthrough pain~* Have received any investigational drug (non-approved) within 30 days prior to the first dose of study medication, or are scheduled to receive an investigational drug other than EN3267 during the course of the study.~* Have hypersensitivities, allergies, or contraindications to fentanyl.~* Have a significant prior history of substance abuse or alcohol abuse.~* May have difficulty complying with the protocol, as assessed by the investigator.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).